<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101270</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01819</org_study_id>
    <secondary_id>ADVL0415</secondary_id>
    <secondary_id>CDR0000401518</secondary_id>
    <secondary_id>COG-ADVL0415</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT00101270</nct_id>
  </id_info>
  <brief_title>Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas</brief_title>
  <official_title>A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of oxaliplatin when given&#xD;
      together with irinotecan in treating young patients with refractory solid tumors or&#xD;
      lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more&#xD;
      sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of oxaliplatin when administered with irinotecan in&#xD;
      pediatric patients with refractory solid tumors or lymphomas.&#xD;
&#xD;
      II. Determine the toxic effects of this regimen in these patients. III. Determine the&#xD;
      pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine, preliminarily, the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      II. Correlate UGT and BCRP genotype with the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of oxaliplatin.&#xD;
&#xD;
      Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on&#xD;
      days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of oxaliplatin until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of oxaliplatin, defined as the maximum dose at which fewer than one-third of patients experience DLT</measure>
    <time_frame>21 days</time_frame>
    <description>Graded using the NCI CTCAE version 3.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response assessed using RECIST criteria</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Childhood Burkitt Lymphoma</condition>
  <condition>Childhood Central Nervous System Germ Cell Tumor</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Liver Cancer</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Malignant Germ Cell Tumor</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Rhabdomyosarcoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Childhood Soft Tissue Sarcoma</condition>
  <condition>Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Childhood Visual Pathway Glioma</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Melanoma</condition>
  <condition>Recurrent Nasopharyngeal Cancer</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <condition>Recurrent Wilms Tumor and Other Childhood Kidney Tumors</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (irinotecan hydrochloride, oxaliplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irinotecan hydrochloride, oxaliplatin)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irinotecan hydrochloride, oxaliplatin)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed refractory malignant solid tumor or lymphoma&#xD;
&#xD;
               -  Intrinsic brain stem tumors and optic pathway tumors do not require histologic&#xD;
                  verification&#xD;
&#xD;
          -  No known curative therapy or therapy proven to prolong survival with an acceptable&#xD;
             quality of life exists&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Evaluable disease is defined as a tumor that cannot be measured using a ruler or&#xD;
                  calipers, but can be assessed to determine disease progression or complete&#xD;
                  response, such as any of the following:&#xD;
&#xD;
                    -  Positive lesions on metaiodobenzylguanidine (MIBG) or bone scan&#xD;
&#xD;
                    -  Metastatic bone marrow disease&#xD;
&#xD;
                    -  Elevated tumor markers&#xD;
&#xD;
                    -  Presence of a malignant pleural effusion&#xD;
&#xD;
          -  No leukemia&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (for patients &gt; 10 years of age)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (for patients ≤ 10 years of age)&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (transfusion allowed)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (for patients age 5 and under)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (for patients age 6 to 10)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (for patients age 11 to 15)&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (for patients age 16 and over)&#xD;
&#xD;
          -  No arrhythmia on EKG&#xD;
&#xD;
          -  No evidence of dyspnea at rest&#xD;
&#xD;
          -  No exercise intolerance&#xD;
&#xD;
          -  Pulse oximetry &gt; 94% on room air and no evidence of pulmonary fibrosis by chest&#xD;
             radiograph* or CT scan&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Weight ≥ 10 kg&#xD;
&#xD;
          -  Neurologic deficits relatively stable for ≥ 1 week before study entry (patients with&#xD;
             CNS tumors only)&#xD;
&#xD;
          -  No electrolyte (e.g., sodium, potassium, bicarbonate, calcium, magnesium, and&#xD;
             phosphate) abnormality ≥ grade 2 (electrolyte supplementation allowed)&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No history of life-threatening allergy to camptothecin derivatives or platinum agents&#xD;
&#xD;
          -  No sensory or motor peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No elevation of amylase or lipase ≥ grade 2&#xD;
&#xD;
          -  Able to tolerate enteral medications (e.g., cefixime, cefpodoxime, or loperamide)&#xD;
&#xD;
          -  Recovered from all prior immunotherapy&#xD;
&#xD;
          -  At least 7 days since prior hematopoietic growth factors&#xD;
&#xD;
          -  At least 7 days since prior antineoplastic biologic therapy&#xD;
&#xD;
          -  Prior stem cell transplantation or rescue without total-body irradiation (TBI) allowed&#xD;
             provided ≥ 3 months have elapsed and there is no evidence of active graft-versus-host&#xD;
             disease&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  Concurrent steroids allowed provided dose has been stable for ≥ 7 days before study&#xD;
             entry&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  Recovered from all prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative small port radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior TBI&#xD;
&#xD;
          -  At least 6 months since prior craniospinal, whole spinal, or whole lung/abdominal&#xD;
             radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to ≥ 50 % of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial radiotherapy to the bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent cephalosporin antibiotics&#xD;
&#xD;
          -  No concurrent use of any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Oxcarbazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Azole antifungal agents&#xD;
&#xD;
               -  Aprepitant&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa McGregor</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>COG Phase I Consortium</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>January 7, 2005</study_first_submitted>
  <study_first_submitted_qc>January 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2005</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

